Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII In The U.S.

Morristown, NJ /PRNewswire/ - Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER®.

The 7.5mg and 15mg strength of Opana ER had U.S. total sales of approximately $21.9 million for the 12 months ending March 31, 2011, according to IMS Health.

Commenting on the launch, Michael Perfetto, Vice President, Sales & Marketing of Actavis, Inc. in the United States said:

"Oxymorphone Extended-Release Tablets offer significant value to our customers and patients. This launch exemplifies Actavis' focus, commitment and capability in bringing complex controlled-release products to our customers."

Please see prescribing information at www.actavis.us/oxymorphone.

About Actavis:
Actavis Inc. is the U.S. distributor of the product and the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis Group hf's sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL.

Actavis Group hf is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,500 employees.

Opana ER ® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

SOURCE Actavis Inc.

Copyright [2011] PR Newswire. All Rights Reserved